191 related articles for article (PubMed ID: 33423937)
1. Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review.
Laukhtina E; Pradere B; Mori K; Schuettfort VM; Quhal F; Mostafaei H; Sari Motlangh R; Katayama S; Grossmann NC; Moschini M; Enikeev D; Shariat SF;
Urol Oncol; 2021 Mar; 39(3):180-190. PubMed ID: 33423937
[TBL] [Abstract][Full Text] [Related]
2. Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder.
Laukhtina E; Pradere B; Lemberger U; Karakiewicz PI; Fajkovic H; Shariat SF
Curr Opin Urol; 2022 Sep; 32(5):561-566. PubMed ID: 35849719
[TBL] [Abstract][Full Text] [Related]
3. Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review.
Laukhtina E; Pradere B; Mori K; Schuettfort VM; Quhal F; Mostafaei H; Sari Motlagh R; Aydh A; Moschini M; Enikeev D; Karakiewicz PI; Abufaraj M; Shariat SF;
Urol Oncol; 2021 Aug; 39(8):471-479. PubMed ID: 33888424
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 testing in urothelial bladder cancer: essentials of clinical practice.
Rouanne M; Radulescu C; Adam J; Allory Y
World J Urol; 2021 May; 39(5):1345-1355. PubMed ID: 33141317
[TBL] [Abstract][Full Text] [Related]
5. Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy?
Turker P; Segersten U; Malmström PU; Hemdan T
Scand J Urol; 2019 Feb; 53(1):45-50. PubMed ID: 30806186
[No Abstract] [Full Text] [Related]
6. The molecular limitations of biomarker research in bladder cancer.
Vlachostergios PJ; Faltas BM
World J Urol; 2019 May; 37(5):837-848. PubMed ID: 30171455
[TBL] [Abstract][Full Text] [Related]
7. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
[TBL] [Abstract][Full Text] [Related]
8. Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.
Lavoie JM; Black PC; Eigl BJ
J Urol; 2019 Jul; 202(1):49-56. PubMed ID: 30730407
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant systemic therapy in patients undergoing nephroureterectomy for urothelial cancer: a multidisciplinary systematic review and critical analysis.
Wu Z; Li M; Wang L; Paul A; Raman JD; Necchi A; Psutka SP; Buonerba C; Zargar H; Black PC; Derweesh IH; Mir MC; Uzzo RG; Pandolfo SD; Autorino R; DI Lorenzo G
Minerva Urol Nephrol; 2022 Oct; 74(5):518-527. PubMed ID: 35383431
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: are we asking the right questions?
Aragon-Ching JB
J Clin Oncol; 2014 Dec; 32(36):4169-70. PubMed ID: 25385734
[No Abstract] [Full Text] [Related]
11. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
[TBL] [Abstract][Full Text] [Related]
12. Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts.
Tse J; Ghandour R; Singla N; Lotan Y
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781730
[TBL] [Abstract][Full Text] [Related]
13. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy in bladder cancer: ready for prime time?
Pouessel D; Gauthier H; Serrate C; Pfister C; Culine S
J Clin Oncol; 2014 Dec; 32(36):4168-9. PubMed ID: 25385728
[No Abstract] [Full Text] [Related]
14. Neoadjuvant phase II studies of modified methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer.
Adesunloye BA
J Clin Oncol; 2014 Dec; 32(36):4170. PubMed ID: 25385733
[No Abstract] [Full Text] [Related]
15. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
[TBL] [Abstract][Full Text] [Related]
16. Everything old is new again! Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer.
Sternberg CN; Apolo AB
J Clin Oncol; 2014 Jun; 32(18):1868-70. PubMed ID: 24821880
[No Abstract] [Full Text] [Related]
17. Re: Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.
Chang SS
J Urol; 2015 Jun; 193(6):1932. PubMed ID: 25986790
[No Abstract] [Full Text] [Related]
18. Bladder cancer: accelerating MVAC.
Killock D
Nat Rev Clin Oncol; 2014 Jul; 11(7):378. PubMed ID: 24863165
[No Abstract] [Full Text] [Related]
19. Bladder cancer: Accelerating MVAC.
Killock D
Nat Rev Urol; 2014 Jun; 11(6):307. PubMed ID: 24861327
[No Abstract] [Full Text] [Related]
20. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
